Condition
Hepatocellular Carcinoma Stage I
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
1 treatments under study, led by Major Hepatectomy
Research Leaders
5 sponsors active, led by National Natural Science Foundation of China
Related Conditions
Often studied with 6 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
Trial Status
Completed2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (3)
Research Network
Common Treatments
- Major Hepatectomy1
Active Sponsors
- National Natural Science Foundation of China1
- AstraZeneca1
- Southwest Hospital, China1
- Hospital Israelita Albert Einstein1
- Anhui Medical University1
Top Investigators
The First Affiliated Hospital of University of Science and Technology of China
Hospital Israelita Albert Einstein
Institute of hepatobiliary surgery,Southwest Hospital
Related Conditions
- Recurrence1
- Hepatocellular Carcinoma Stage Ii1
- Hepatocellular Carcinoma By Bclc Stage1
- Hepatocellular Carcinoma Stage Iii1
- Radiofrequency Ablation1